People Power: How The Crowd May Shape The Funding And Development Of Drugs
Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.
You may also be interested in...
Research collaboration will give FDA access to individual drug safety reports from patient network’s 350,000 members and could lead to future projects on post-market surveillance.
Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese
Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.
Plus news on recent financings by Elcelyx, Jounce Therapeutics, Retrophin and e-Therapeutics.